Stay updated on Amivantamab in Esophagogastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.

Latest updates to the Amivantamab in Esophagogastric Cancer Clinical Trial page
- Check6 days agoChange DetectedNew update entries for 2026-02-12 and 2026-02-17 were added and older 2025 entries removed, updating the study record’s last-update information and QC status.SummaryDifference0.2%

- Check14 days agoChange DetectedThe page now displays Revision: v3.4.2, and previous notices about government funding lapses and the prior v3.4.1 update have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding notice about NIH operations and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a glossary toggle and updated metadata labels (QC criteria status and FEAR Act data). The page revision was updated to v3.4.0.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4; no substantive content changes to the trial details were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedExpanded and reorganized the study's site information by adding a generic Locations section and listing sites in California, Massachusetts, New Jersey, and New York. The previous state-specific location blocks were removed.SummaryDifference0.6%

Stay in the know with updates to Amivantamab in Esophagogastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.